Expression of genes coding for pS2, c‐erbB2, estrogen receptor and the H23 breast tumor‐associated antigen

Zaretsky, Joseph Z.; Weiss, Mordechai; Tsarfaty, Ilan; Hareuveni, Mara; Wreschner, Daniel H.; Keydar, Iafa

doi:10.1016/0014-5793(90)80880-r

Cited by 53 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…pS2 expression was detected in 29% of the breast cancers studied, which is within the range (22-58%) for mRNA detection in breast cancer reported by others (Rio et al, 1987;Stack et al, 1988;Skilton et al, 1989;Henry et al, 1990;Zaretsky et al, 1990;Hahnel et al, 1991;Delvenne et al, 1992;Wysocki et al, 1994) and similar to the range of 27-68% of breast cancers that express pS2 protein (Foekens et al, 1990;Henry et al, 1991;Schwartz et al, 1991;Walker et al, 1995;Tutschek et al, 1996). The more recent development of reverse transcription polymerase chain reaction (RT-PCR), which may be a more sensitive method to detect pS2, allows both the detection and quantification of pS2 mRNA expression (Carr et al, 1995).…”

Section: Discussionsupporting

confidence: 83%

PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer

Thompson

Elton²,

Hawkins³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Expression of pS2, an oestrogen-regulated gene, has been associated with a good short-term prognosis and response to endocrine therapy. The aim of this study was to determine whether expression of mRNA for the pS2 gene in breast cancer could contribute useful information on disease behaviour and survival at medium-term follow-up. Northern blotting was used to detect pS2 messenger ribonucleic acid (mRNA) in the primary tumour tissue from each of 90 patients with breast cancer. Axillary node status was established by sampling or clearance, oestrogen receptor concentration by enzyme immunosorbant assay and follow-up was continued for at least 6 years or until death. At 83 months mean follow-up, 29 of 90 (32%) patients had recurrent disease and, of these, 18 (20%) had died from breast cancer. pS2 mRNA expression, present in 26 of 90 (29%) cancers, was associated with freedom from disease recurrence (P = 0.026) and was significantly associated with survival at a minimum of 6 years follow-up (P < 0.001). Pathological node status and tumour size were also significantly associated with disease recurrence (P < 0.001 and P = 0.002 respectively) and inversely with survival (P < 0.001 and P < 0.001 respectively). After multiple Cox regression analysis, pS2 expression was still a significant predictor of recurrence (but not survival) after adjusting for node status and tumour size; oestrogen receptor was an independent predictor of survival. The combination of node status and pS2 expression discriminated patients with particularly good prognosis (node negative, pS2 positive: no mortality at 6 years) or poor prognosis (node positive, pS2 negative; 41% mortality at 6 years). Evaluation of pS2 expression in breast cancer at diagnosis may provide additional useful prognostic information to conventional staging.

show abstract

Section: Discussionsupporting

confidence: 83%

PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer

Thompson

Elton²,

Hawkins³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…It is still not clear why the gene coding for H23 antigen mRNA is overexpressed in these cancers. As one of its forms is probably a transmembrane receptor-like protein, it may be an element of signal transduction and, therefore, reflect an involvement in cell growth (26,27).…”

Section: Discussionmentioning

confidence: 99%

The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer

Verkooijen¹,

Smit²,

Romijn³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

Objective: The aim of the present study is to assess the prevalence of second primary tumors in patients treated for thyroid cancer. Furthermore, we wanted to assess the standardized risk rates for all second primary tumors, but especially for breast cancer, as data in the literature indicate an excessive risk in differentiated thyroid cancer (DTC) patients for this tumor. Materials and methods: We included consecutive patients, who received ablation treatment with I-131 at the Leiden University Medical Center between January 1985 and December 1999 (nZ282). The mean period of follow-up was 10.6G4.1 years. Results: Thirty-five of the 282 patients (12.4%) had a second primary tumor (SPT), either preceding or following the diagnosis of thyroid cancer. Five other patients had three primary tumors, including DTC. As a result, 40 additional tumors were found in this group, revealing an overall prevalence of 14.2%. Twenty tumors (7.1%) preceded the thyroid cancer with a mean interval of 5.7 years (range: 0.5-22.0 years), whereas 20 tumors (7.1%) occurred after this tumor with a mean interval of 6.7 years (range: 1.0-15.0 years). In 13 female patients, breast cancer was found as SPT. The standardized incidence rate (SIR) for all cancers after the diagnosis of DTC in this study population was not increased (1.13; confidence interval (CI): 0.68-1.69). However, we found an increased SIR of 2.26 (CI: 1.60-3.03) for all cancers either following or preceding DTC, which is mainly caused by a SIR of 3.95 (CI: 2.06-6.45) for breast cancer. Conclusion: Patients with DTC have an overall increased standardized incidence rate for second primary tumors, but not for second primary tumors following I-131 therapy. These findings suggest a common etiologic and/or genetic mechanism instead of a causal relation.European Journal of Endocrinology 155 801-806

show abstract

“…It is overexpressed in many tumor types including breast, pancreatic, lung, prostate, and ovarian (21 -23). The incidence of MUC1 overexpression in breast and pancreatic tumors has been reported to be as high as 90% (24,25) and recent reports have also shown MUC1 overexpression in hematologic malignant diseases, such as B-cell lymphoma and multiple myeloma (24 -26). Elevated MUC1 expression is associated with increased metastatic potential and poor patient survival (21,23).…”

Section: Introductionmentioning

confidence: 99%

In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter

Dwyer¹,

Bergert²,

O’Connor

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Expression of the sodium iodide symporter (NIS) in the thyroid gland provides for effective imaging and treatment of thyroid cancer using radiolabeled iodide. Transfer of NIS into other tumors would expand the utility of this treatment to tumors of nonthyroid origin. MUC1 is a transmembrane glycoprotein that is overexpressed in many tumor types, including breast, pancreatic, and ovarian. The aim of this study was to create a construct containing NIS under the control of the MUC1 promoter to target expression specifically to MUC1-positive breast cancer cells.Experimental Design: A replication-deficient adenoviral construct was created containing the MUC1 promoter followed by the human NIS gene. Iodide uptake assays, Western blot, and immunohistochemistry were used to confirm NIS expression and function. Breast cancer xenografts in mice were infected with Ad5/MUC1/NIS and then imaged and treated using radioiodide.Results: A 58-fold increase in iodide uptake was observed in infected MUC1-positive T47D cells with no significant increase observed in MUC1-negative MDA-MB-231 cells or in cells infected with the control virus. The in vivo study yielded clear images of Ad/MUC1/NISinfected tumor xenografts using 123 I. Administration of a therapeutic dose of 131 I resulted in an 83% reduction in tumor volume, whereas control tumors continued to increase in size (P < 0.01).Conclusions: These results show that the MUC1 promoter is capable of directing efficient and selective expression of the NIS gene in MUC1-positive breast tumor cells. This could potentially have applications for both imaging and therapy in a range of MUC1-positive tumor types.

show abstract

Expression of genes coding for pS2, c‐erbB2, estrogen receptor and the H23 breast tumor‐associated antigen

Cited by 53 publications

References 17 publications

PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer

PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer

The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer

In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter

Contact Info

Product

Resources

About